Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene

Drug Metabolism and Disposition

Volumn 37, Issue 10, 2009, Pages 1999-2007

  Olson, Kristine C ^a,b   Dellinger, Ryan W ^a,b   Zhong, Qing ^a,b   Sun, Dongxiao ^a,b   Amin, Shantu ^a,b   Spratt, Thomas E ^a,b   Lazarus, Philip ^a,b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CYSTEINE; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A9; GLYCINE; METHIONINE; POLYACRYLAMIDE GEL; THREONINE; VALINE;

AFRICAN AMERICAN; AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; CHEEK; CODON; DIMERIZATION; DNA SEQUENCE; EUROPEAN AMERICAN; GENE; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC TRAIT; GENETIC VARIABILITY; GLUCURONIDATION; GLUCURONOSYLTRANSFERASE 1A9 GENE; HUMAN; HUMAN CELL; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING; WILD TYPE;

AFRICAN AMERICANS; ALLELES; AMINO ACID SUBSTITUTION; CELL LINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MICROSOMES, LIVER; MUTATION; POLYMORPHISM, GENETIC; PREVALENCE;

EID: 70349294431     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.024596     Document Type: Article

References (39)

1. Al-Zoughool M and Talaska G (2005) High-performance liquid chromatography method for determination of N-glucuronidation of 4-aminobiphenyl by mouse, rat, and human liver microsomes. Anal Biochem 340:352-358. (Pubitemid 40544875)
2. Al-Zoughool M and Talaska G (2006) 4-Aminobiphenyl N-glucuronidation by liver microsomes: optimization of the reaction conditions and characterization of the UDP-glucuronosyltransferase isoforms. J Appl Toxicol 26:524-532. (Pubitemid 44862552)
3. Araki J, Kobayashi Y, Iwasa M, Urawa N, Gabazza EC, Taguchi O, Kaito M, and Adachi Y (2005) Polymorphism of UDP-glucuronosyltransferase 1A7 gene: a possible new risk factor for lung cancer. Eur J Cancer 41:2360-2365. (Pubitemid 41415614)
4. Bernard O and Guillemette C (2004) The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775-778. (Pubitemid 38955603)
5. Burchell B and Hume R (1999) Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol 14:960-966. (Pubitemid 29487290)
6. Chen C, Brinkworth R, and Waters MJ (1997) The role of receptor dimerization domain residues in growth hormone signaling. J Biol Chem 272:5133-5140. (Pubitemid 27090070)
7. Ciotti M, Lakshmi VM, Basu N, Davis BD, Owens IS, and Zenser TV (1999) Glucuronidation of benzidine and its metabolites by cDNA-expressed human UDP-glucuronosyltransferases and pH stability of glucuronides. Carcinogenesis 20:1963-1969. (Pubitemid 29476124)
8. Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, and Lazarus P (2007) Glucuronidation of PhIP and N-OH-PhIP by UDP- glucuronosyltransferase 1A10. Carcinogenesis 28:2412-2418. (Pubitemid 350111602)
9. Dellinger RW, Fang JL, Chen G, Weinberg R, and Lazarus P (2006) Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos 34:943-949. (Pubitemid 43763749)
10. Elahi A, Bendaly J, Zheng Z, Muscat JE, Richie JP Jr, Schantz SP, and Lazarus P (2003) Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 98:872-880. (Pubitemid 36959285)
11. Fang JL, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, and Lazarus P (2002) Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res 62:1978-1986. (Pubitemid 34408441)
12. Fujiwara R, Nakajima M, Yamanaka H, and Yokoi T (2009) Key amino acid residues responsible for the differences in substrate specificity of human UDP-glucuronosyltransferase (UGT)1A9 and UGT1A8. Drug Metab Dispos 37:41-46.
13. Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, and Guillemette C (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617. (Pubitemid 36329379)
14. Galetin A, Clarke SE, and Houston JB (2002) Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 30:1512-1522. (Pubitemid 35397061)
15. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, et al. (2002) Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10:1239-1248.
16. Ghosh SS, Lu Y, Lee SW, Wang X, Guha C, Roy-Chowdhury J, and Roy-Chowdhury N (2005) Role of cysteine residues in the function of human UDP glucuronosyltransferase isoform 1A1 (UGT1A1). Biochem J 392:685-692. (Pubitemid 43022749)
17. Ghosh SS, Sappal BS, Kalpana GV, Lee SW, Chowdhury JR, and Chowdhury NR (2001) Homodimerization of human bilirubin-uridine-diphosphoglucuronate glucuronosyltransferase-1 (UGT1A1) and its functional implications. J Biol Chem 276:42108-42115. (Pubitemid 37371117)
18. Guéraud F and Paris A (1998) Glucuronidation: a dual control. Gen Pharmacol 31:683-688.
19. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
20. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685. (Pubitemid 41345319)
21. Mano Y, Usui T, and Kamimura H (2004) Effects of β-estradiol and propofol on the 4-methylumbelliferone glucuronidation in recombinant human UGT isozymes 1A1, 1A8 and 1A9. Biopharm Drug Dispos 25:339-344. (Pubitemid 39534439)
22. Nagar S and Remmel RP (2006) Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25:1659-1672.
23. Ockenga J, Vogel A, Teich N, Keim V, Manns MP, and Strassburg CP (2003) UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer. Gastroenterology 124:1802-1808. (Pubitemid 36666777)
24. Operaña TN and Tukey RH (2007) Oligomerization of the UDP-glucuronosyltransferase 1A proteins: homo- and heterodimerization analysis by fluorescence resonance energy transfer and co-immunoprecipitation. J Biol Chem 282:4821-4829. (Pubitemid 47100945)
25. Owens IS and Ritter JK (1995) Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. Prog Nucleic Acid Res Mol Biol 51:305-338.
26. Park LY, Muscat JE, Kaur T, Schantz SP, Stern JC, Richie JP Jr, and Lazarus P (2000) Comparison of GSTM polymorphisms and risk for oral cancer between African Americans and Caucasians. Pharmacogenetics 10:123-131. (Pubitemid 30193074)
27. Ralston SL, Seidel A, Luch A, Platt KL, and Baird WM (1995) Stereoselective activation of dibenzo[a,l]pyrene to (-)-anti(11R,12S,13S,14R)- and (+)-syn(11S,12R,13S,14R)-11,12-diol-13,14-epoxides which bind extensively to deoxyadenosine residues of DNA in the human mammary carcinoma cell line MCF-7. Carcinogenesis 16:2899-2907. (Pubitemid 26004184)
28. Ren Q, Murphy SE, Zheng Z, and Lazarus P (2000) O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 28:1352-1360. (Pubitemid 30797120)
29. Richie JP Jr, Carmella SG, Muscat JE, Scott DG, Akerkar SA, and Hecht SS (1997) Differences in the urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in black and white smokers. Cancer Epidemiol Biomarkers Prev 6:783-790.
30. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T, Amin S, and Lazarus P (2007) Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 35:2006-2014. (Pubitemid 350010805)
31. Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, and Takeuchi Y (2008) Effect of D256N and Y483D on propofol glucuronidation by human uridine 5′-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol 103:131-136. (Pubitemid 352019722)
32. Tephly TR and Burchell B (1990) UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends Pharmacol Sci 11:276-279.
33. Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, Perusse L, et al. (2006) Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 66:125-133. (Pubitemid 43166017)
34. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616. (Pubitemid 30340694)
35. Uchaipichat V, Galetin A, Houston JB, Mackenzie PI, Williams JA, and Miners JO (2008) Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol 74:1152-1162.
36. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423. (Pubitemid 38420275)
37. Villeneuve L, Girard H, Fortier LC, Gagné JF, and Guillemette C (2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307:117-128. (Pubitemid 37151897)
38. Wiener D, Fang JL, Dossett N, and Lazarus P (2004) Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone glucuronidation phenotype in human liver microsomes. Cancer Res 64:1190-1196. (Pubitemid 38176928)
39. Zheng Z, Park JY, Guillemette C, Schantz SP, and Lazarus P (2001) Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst 93:1411-1418. (Pubitemid 32936819)